Shenyang Xingqi Pharmaceutical Co Ltd. Stock Analysis 300573.SZ

Shenyang Xingqi Pharmaceutical Co., Ltd. engages in the research, development, production, and sale of ophthalmic drugs. The company is headquartered in Shenyang, Liaoning and currently employs 2,396 full-time employees. The company went IPO on 2016-12-08. The firm's main products include drugs for delaying the progression of myopia in children, drugs for the treatment of dry eyes, ophthalmic anti-infective drugs, ophthalmic anti-inflammatory/anti-infective drugs, pupil dilatant and ciliary muscle paralyzer drugs, ophthalmic non-steroidal anti-inflammatory drugs, miotic drugs, anti-glaucoma drugs and others. The firm is also engaged in health food production, inspection and testing services, drug import and export, plastic product manufacturing, non-residential real estate leasing, machinery and equipment leasing and other businesses. The firm mainly operates its businesses in the domestic market.